Literature DB >> 12846686

Can contrast-enhanced MR imaging predict survival in breast cancer?

B Boné1, B K Szabó, L G Perbeck, B Veress, P Aspelin.   

Abstract

PURPOSE: To investigate the value of pre-operative contrast-enhanced MR imaging (CE-MRI) in predicting the disease-free and overall survival in breast cancer.
MATERIAL AND METHODS: The study population consisted of 50 consecutive patients with histopathologically verified primary breast cancer who pre-operatively underwent CE-MRI examination between 1992 and 1993. A three-time point MR examination was performed where the enhancement rates (C1 and C2), signal enhancement ratio (SER=C1/C2) and washout (W=C1-C2) were calculated. The relation of these MR parameters to disease-free and overall survival was investigated. The median follow-up for surviving patients was 95 months. Univariate and multivariate statistical analyses were performed to evaluate the impact of different factors on prediction of survival.
RESULTS: Of the MR parameters examined at univariate analysis, increased C1 (p=0.029), W (p=0.0081) and SER values (p=0.0081) were significantly associated with shorter disease-free survival, and only C1 (p=0.016) was related significantly to overall survival. Multivariate analysis for disease-free survival showed that the SER (p=0.014) and tumor size (p=0.001) were significant and independent predictors. Age (p=0.003), lymph node status (p=0.014), tumor size (p=0.039) and proliferating cell nuclear antigen index (p=0.053) remained independently associated with overall survival at multivariate analysis. C1 was not confirmed as an independent predictor of overall survival.
CONCLUSION: Our findings support the presumption that CE-MRI is useful in predicting the disease-free survival in patients with breast cancer.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12846686     DOI: 10.1080/j.1600-0455.2003.00080.x

Source DB:  PubMed          Journal:  Acta Radiol        ISSN: 0284-1851            Impact factor:   1.701


  12 in total

1.  Prognostic value of DCE-MRI in breast cancer patients undergoing neoadjuvant chemotherapy: a comparison with traditional survival indicators.

Authors:  Martin D Pickles; Martin Lowry; David J Manton; Lindsay W Turnbull
Journal:  Eur Radiol       Date:  2014-11-26       Impact factor: 5.315

2.  Prediction of disease-free survival in patients with squamous cell carcinomas of the head and neck using dynamic contrast-enhanced MR imaging.

Authors:  S Chawla; S Kim; L A Loevner; W-T Hwang; G Weinstein; A Chalian; H Quon; H Poptani
Journal:  AJNR Am J Neuroradiol       Date:  2011-02-24       Impact factor: 3.825

3.  Correlation between voxel-wise enhancement parameters on DCE-MRI and pathological prognostic factors in invasive breast cancers.

Authors:  Rubina Manuela Trimboli; Marina Codari; Katia Khouri Chalouhi; Ileana Ioan; Giovanna Lo Bue; Arianna Ottini; Daniela Casolino; Luca Alessandro Carbonaro; Francesco Sardanelli
Journal:  Radiol Med       Date:  2017-09-25       Impact factor: 3.469

4.  Correlation of contrast-enhanced ultrasound kinetics with prognostic factors in invasive breast cancer.

Authors:  Botond K Szabó; Ariel Saracco; Ervin Tánczos; Peter Aspelin; Karin Leifland; Brigitte Wilczek; Rimma Axelsson
Journal:  Eur Radiol       Date:  2013-07-03       Impact factor: 5.315

5.  Real-Time Measurement of Functional Tumor Volume by MRI to Assess Treatment Response in Breast Cancer Neoadjuvant Clinical Trials: Validation of the Aegis SER Software Platform.

Authors:  David C Newitt; Sheye O Aliu; Neil Witcomb; Gal Sela; John Kornak; Laura Esserman; Nola M Hylton
Journal:  Transl Oncol       Date:  2014-02-01       Impact factor: 4.243

6.  Invasive breast cancer: predicting disease recurrence by using high-spatial-resolution signal enhancement ratio imaging.

Authors:  Ka-Loh Li; Savannah C Partridge; Bonnie N Joe; Jessica E Gibbs; Ying Lu; Laura J Esserman; Nola M Hylton
Journal:  Radiology       Date:  2008-07       Impact factor: 11.105

7.  Metabolic and vascular features of dynamic contrast-enhanced breast magnetic resonance imaging and (15)O-water positron emission tomography blood flow in breast cancer.

Authors:  Peter R Eby; Savannah C Partridge; Steven W White; Robert K Doot; Lisa K Dunnwald; Erin K Schubert; Brenda F Kurland; Constance D Lehman; David A Mankoff
Journal:  Acad Radiol       Date:  2008-10       Impact factor: 3.173

8.  Kinetic assessment of breast tumors using high spatial resolution signal enhancement ratio (SER) imaging.

Authors:  Ka-Loh Li; Roland G Henry; Lisa J Wilmes; Jessica Gibbs; Xiaoping Zhu; Ying Lu; Nola M Hylton
Journal:  Magn Reson Med       Date:  2007-09       Impact factor: 4.668

9.  Relationship between morphological features and kinetic patterns of enhancement of the dynamic breast magnetic resonance imaging and clinico-pathological and biological factors in invasive breast cancer.

Authors:  Oscar Fernández-Guinea; Alejandro Andicoechea; Luis O González; Salomé González-Reyes; Antonio M Merino; Luis C Hernández; Alfonso López-Muñiz; Paz García-Pravia; Francisco J Vizoso
Journal:  BMC Cancer       Date:  2010-01-08       Impact factor: 4.430

10.  Estimating breast tumor blood flow during neoadjuvant chemotherapy using interleaved high temporal and high spatial resolution MRI.

Authors:  Leonidas Georgiou; Nisha Sharma; David A Broadbent; Daniel J Wilson; Barbara J Dall; Anmol Gangi; David L Buckley
Journal:  Magn Reson Med       Date:  2017-04-03       Impact factor: 4.668

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.